Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.

CONCLUSIONS: Both treatment strategies produce equivalent and better than expected outcomes compared to historical controls for N2 NSCLC, with no differences in recurrence patterns. How these conventional therapeutic strategies will compare to those involving immunotherapy combined with surgical loco-regional disease control for N2 disease remains to be determined.
PMID: 30227129 [PubMed - as supplied by publisher]

Source: The Annals of Thoracic Surgery - September 15, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Spicer JD, Shewale JB, Nelson DB, Mitchell KG, Bott MJ, Vallières E, Wilshire CL, Vaporciyan AA, Swisher SG, Jones DR, Darling GE, Sepesi B Tags: Ann Thorac Surg Source Type: research